Wall Street Remains Bullish On Lantheus Holdings, Inc. (LNTH)
Lantheus Holdings, Inc. (NASDAQ:LNTH) is among the cheap healthcare stocks to buy heading into 2026. As of December 7, Lantheus Holdings, Inc.
Lantheus Holdings Inc. (LNTH)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Farallon Capital Thomas Steyer | 3,477,227 | $178,346,973 | -49% | 0.73% |
| 2. | Polaris Capital Management Bernard Horn | 637,300 | $32,687,117 | 2.15% | |
| 3. | 30,500,000 | $32,092,799 | +20% | 0.82% | |
| 4. | Private Capital Management Gregg J. Powers | 560,664 | $28,756,457 | +4% | 2.57% |
| 5. | 27,000,000 | $28,393,353 | 0.01% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $18.60 | 1,000 | $18,600.00 | 16,211 | 2021-03-05 | Filing | |
| $18.02 | 1,000 | $18,020.00 | 15,211 | 2021-02-26 | Filing | |
| $19.39 | 1,000 | $19,390.00 | 14,211 | 2021-02-19 | Filing | |
| $20.03 | 1,000 | $20,030.00 | 13,211 | 2021-02-12 | Filing | |
| $17.94 | 1,000 | $17,940.00 | 12,211 | 2021-02-05 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $56.15 | 3,365,000 | $188,944,750.00 | 3,477,227 | 2025-08-20 | Filing | |
| $55.34 | 41,000 | $2,268,940.00 | 6,842,227 | 2025-08-19 | Filing | |
| $56.15 | 3,365,000 | $188,944,750.00 | 3,477,227 | 2025-08-20 | Filing | |
| $55.34 | 41,000 | $2,268,940.00 | 6,842,227 | 2025-08-19 | Filing | |
| $53.57 | 3,060 | $163,924.20 | 108,214 | 2025-08-13 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 8,265,745 | $423,950,039 | 0.01% | |
| 2. | 6,952,418 | $356,589,519 | 0.01% | |
| 3. | 6,684,737 | $342,856,339 | 0.16% | |
| 4. | 4,198,972 | $215,365,267 | 0.01% | |
| 5. | 3,878,152 | $198,910,527 | 0.01% |
News See All
12 Cheap Healthcare Stocks to Buy Heading into 2026
Since the pandemic, healthcare is one of the sectors that have remained in the spotlight even amid market twists.
Lantheus Holdings, Inc. (NASDAQ:LNTH) Q3 2025 Earnings Call Transcript
Operator: Good morning. Welcome to Lantheus' Third Quarter 2025 Conference Call.
Here’s Why Lantheus Holdings (LNTH) Fell in Q3
Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Small Cap Growth Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here.
Goldman Sachs Downgrades Lantheus (LNTH) PT to $77 Amid PYLARIFY Pricing Pressure, Slow Alzheimer's Drug Uptake
Lantheus Holdings Inc. (NASDAQ:LNTH) is one of the best value stocks to invest in now. On October 8, Goldman Sachs downgraded Lantheus to Neutral from Buy with a price target of $77, down from $110.
10 Best Value Stocks to Invest in Now
On October 7, Lori Calvasina, RBC Capital Markets head of US equity strategy, joined CNBC's 'Power Lunch' to discuss Calvasina's thoughts on current valuations.
FDA Accepts Lantheus Holdings, Inc. (LNTH)’ NDA for New PSMA Imaging Agent
Lantheus Holdings, Inc. (NASDAQ:LNTH), a leader in radiopharmaceuticals, is strengthening its position in diagnostic and therapeutic imaging with several recent milestones.
11 Best Pharma Stocks to Invest in for the Long Term
According to a recent White House announcement, President Trump wrote letters to 17 major pharmaceutical companies outlining the actions they could take to bring the prices of prescription pharmaceuticals...
Leerink Partners Maintains a Buy on Lantheus Holdings (LNTH) With a $99 PT
Lantheus Holdings, Inc. (NASDAQ:LNTH) is one of the best high growth low PE stocks to invest in now.
13 High Growth Low PE Stocks to Invest In Now
On August 25, Zeina Bain, managing partner at Sullivan Street Partners, appeared on CNBC to talk about how investors will cycle further into equities following Fed Chair Jerome Powell’s dovish speech...